过去 90 天内有 1 名内部人买入 €26.9万股票，最近一笔由 Alexandre Fraichard 披露于 2026年11月02日。
Genoway：高管交易动态
Genoway属于医疗与制药行业。其高管的申报经由AMF发布。过去一年（2025年11月2日至2026年11月2日），共有13份申报出自6位高管。
买卖两个方向都有交易：8笔买入，金额€52.1万，4笔卖出，金额€5.7万，分别来自3位高管和4位高管。买卖相抵后，净额为买入€46.4万。与股份授予不同，公开市场买入由高管本人按市价出资。期内单笔金额最大的是一笔买入，金额€19.0万，申报人为Alexandre Fraichard，于2026年9月30日公布，相当于市值的0.66%。买方中包括2位董事和1位首席执行官。
有记录的最近一笔买入公布于2026年11月2日，即5天前。从交易发生到出现在AMF的披露中，中位时长为3天。根据欧盟《市场滥用条例》（MAR）第19条，高管须在三个工作日内申报其交易。
十二个月内共13份申报，高于我们在同一交易所跟踪的312家公司的中位数（7份申报）。回溯至覆盖起点2021年，高管共申报18笔买入和19笔卖出。
同一行业中，我们的信号近期也捕捉到以下公司的高管买入：Dynavox Group AB和UCB。本摘要仅基于AMF的披露信息，不预示股价未来走向。
谁在何时交易
买入卖出内部人买入以来
- -15.2%入场价 €2.44 · 2026年10月30日 收盘 €2.07
- -11.5%入场价 €2.34 · 2026年10月30日 收盘 €2.07
- -21.9%入场价 €2.65 · 2026年10月30日 收盘 €2.07
入场价为披露次日收盘价，即读者可操作的第一个价格。价格以上市货币计。过往涨跌不代表未来表现。
透明的价值 + 质量排名，独立于内部人交易信号。
财务数据
财年 2025财年截至 2025年12月 · cache
- 4,539 股@ €2.10340.037% 占市值1.3% 占其流量股票Euronext Growth ParisISIN FR00040535102026DD1147784标准退出：2027年1月28日 (T+90)
- 18,100 股@ €2.16660.14% 占市值5.6% 占其流量股票Euronext Growth ParisISIN FR00040535102026DD1146174标准退出：2027年1月21日 (T+90)
- 13,750 股@ €2.16450.11% 占市值4.5% 占其流量股票Euronext Growth ParisISIN FR00040535102026DD1143583标准退出：2027年1月8日 (T+90)
- 80,999 股@ €2.34830.66% 占市值30.1% 占其流量股票Euronext Growth ParisISIN FR00040535102026DD1141180标准退出：2026年12月28日 (T+90)
- 35,850 股@ €2.4960.30% 占市值20.3% 占其流量股票Euronext Growth ParisISIN FR00040535102026DD1129724标准退出：2026年10月25日 (T+90)
- 25,000 股@ €2.420.20% 占市值13.7% 占其流量股票Euronext Growth ParisISIN FR00040535102026DD1127628标准退出：2026年10月14日 (T+90)
- 5,000 股@ €2.400.041% 占市值50.5% 占其流量股票Euronext ParisISIN FR00040535102026DD1122093标准退出：2026年8月26日 (T+90)
- 4,870 股@ €2.400.040% 占市值100.0% 占其流量股票Euronext ParisISIN FR00040535102026DD1122087
- 4,900 股@ €2.400.041% 占市值49.5% 占其流量股票Euronext ParisISIN FR00040535102026DD1122089
- 10,000 股@ €2.400.083% 占市值100.0% 占其流量股票Euronext ParisISIN FR00040535102026DD1122091
- 4,044 股@ €2.400.032% 占市值9.7% 占其流量股票Euronext ParisISIN FR00040535102026DD1117343
- 38,500 股@ €2.3590.3% 占其流量股票Euronext ParisISIN FR00040535102025DD1086013标准退出：2026年3月17日 (T+90)
- 42,553 股@ €2.3525.3% 占其流量股票场外交易ISIN FR00040535102025DD1085526
- 516 股@ €2.805.1% 占其流量股票Euronext Growth ParisISIN FR00040535102025DD1032064标准退出：2025年7月10日 (T+90)
- 484 股@ €2.804.6% 占其流量股票Euronext Growth ParisISIN FR00040535102025DD1032064-T2标准退出：2025年7月14日 (T+90)
- 11,299 股@ €3.06997.9% 占其流量股票Euronext Growth ParisISIN FR00040535102025DD1029025标准退出：2025年6月29日 (T+90)
- 12,500 股@ €3.04438.6% 占其流量股票Euronext ParisISIN FR00040535102025DD1018016标准退出：2025年5月1日 (T+90)
- 3,880 股@ €3.9053.3% 占其流量股票Euronext Growth ParisISIN FR00040535102024DD997920
- 1,700 股@ €4.8028.7% 占其流量股票Euronext Growth ParisISIN FR00040535102024DD946637
- 5,000 股@ €4.4029.6% 占其流量股票Euronext Growth ParisISIN FR00040535102023DD942884
- 500 股@ €4.207.4% 占其流量股票Euronext Growth ParisISIN FR00040535102023DD939782
- 400 股@ €3.9255.5% 占其流量股票Euronext ParisISIN FR00040535102023DD935006
- 700 股@ €3.92928.5% 占其流量股票Euronext ParisISIN FR00040535102023DD935006-T2
- 5,000 股@ €4.0026.9% 占其流量股票Euronext ParisISIN FR00040535102023DD929353标准退出：2023年12月24日 (T+90)
- 41,344 股@ €3.87100.0% 占其流量股票Euronext ParisISIN FR00040535102023DD913833
38 条申报中的 25 条
About Genoway
genOway is a French biotechnology company listed on Euronext Growth Paris under ticker ALGEN and ISIN FR0004053510. Founded in 1999 and headquartered in Lyon, France, the company designs, develops and commercializes genetically modified preclinical models, mainly mice, rats and cell lines, for pharmaceutical companies, biotech groups and academic institutions. Its core mission is to better “mimic” humans and disease biology in order to improve the predictive power of preclinical research and help drug developers identify the most effective and safest candidates earlier in the R&D process. The group relies on a technological platform supported by exclusive worldwide licenses and advanced gene-editing expertise, enabling it to create knockout, knock-in, humanized, conditional and inducible models tailored to specific scientific needs.
Historically, genOway built its reputation around customized models, but it has progressively expanded into a proprietary catalog of translational off-the-shelf models. Since 2018, this catalog has been particularly focused on immuno-oncology and immunotherapy, two high-growth areas in modern drug discovery. The company also provides bespoke model-generation services for target validation, drug screening, efficacy studies and non-regulatory safety testing. This hybrid model — combining high-value custom projects with recurring catalog products — is central to genOway’s competitive positioning and long-term growth profile.
展开全文收起
The company has a meaningful international footprint. genOway employs more than 140 people representing 17 nationalities, serves customers in 28 countries across five continents, and works with 380 academic institutions and 170 life sciences companies, including 17 of the world’s top 20 pharmaceutical companies. Its commercial reach is supported by an international network of affiliates and distributors across North America, Europe and Asia, as well as a reinforced presence in China through a Shanghai joint venture. This geographic diversification strengthens its proximity to major research hubs and supports its international expansion strategy.
From a strategic and financial standpoint, genOway has emphasized sustained organic growth, driven by catalog expansion, commercial organization upgrades and the ROUTE50+ strategy, later extended into ROUTE50+DATA. The company has also highlighted improved profitability, with EBITDA margins above its 15% target threshold, and continues to communicate ambitions for double-digit growth. Overall, genOway is a specialized, science-driven and internationally oriented preclinical research company operating at the intersection of biotechnology, gene editing and outsourced services for the pharmaceutical industry.
同行业近期入选信号
我们的模型当前为推荐列表排序的买入。
全部推荐
